December 22, 2025

FDA Approves New Treatment for Lung Fibrosis

Nerandomilast becomes first preferential PDE4B inhibitor approved for PPF, slowing FVC decline in phase 3 trial

Conexiant

December 11, 2025

What Drives Progression Despite TNFi?

Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.

Conexiant

December 10, 2025

A New Question for Chronic Pain

A new clinical feature–based self-referral tool shows promise for speeding the diagnosis of axial spondyloarthritis.

Conexiant

December 10, 2025

Medical Oddities: Hot Flashes, Prepare to Be Hypnotized

Your weekly grab bag: mouthwash spice, hypnotic cool-downs, muscle tea, fiber fixes, telomere buzz.

Conexiant

December 10, 2025

Dual Therapy Shows Bone Promise

Adding romosozumab to ongoing denosumab therapy boosted bone formation and improved spine density in postmenopausal women with severe osteoporosis.

Conexiant

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

December 05, 2025

Top 10 States to Practice Rheumatology

The following list highlights the states that offer the most favorable conditions for rheumatologists.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News